This article is more than 5 years old. Information may no longer be current.

Novel bone regeneration material approved for sale in Europe

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The German company curasan AG announced it has received European approval for a novel synthetic bone regeneration material.

Osseolive is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation, the company noted in a press release.

“With Osseolive emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products”, stated Hans Dieter Rössler, curasan AG CEO. “Osseolive has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”